AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05054686 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Strengthening, Stretching and Aerobic Exercises at clinic
Description: In this group of knee osteoarthritis patients will be applied all stretching, strengthening and 30 minutes bicycle exercises in the same session, only 30 minutes walking will be given as home program.
Study NCT00978393 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: liraglutide
Description: High dose liraglutide treatment (3.0 mg) followed by low dose liraglutide treatment (1.8 mg). Injected s.c. (under the skin) once daily in the evening.
Study NCT02394665 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intensity Modulated Radiation Therapy
Description: IMRT treatment will consist of 60 Gy in 30 fractions to PTV 60
Study NCT00978393 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: liraglutide
Description: Low dose liraglutide treatment (1.8 mg) followed by high dose liraglutide treatment (3.0 mg). Injected s.c. (under the skin) once daily in the evening.
Study NCT00978393 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: liraglutide
Description: Low dose liraglutide treatment (1.8 mg) followed by high placebo treatment (3.0 mg). Injected s.c. (under the skin) once daily in the evening.
Study NCT00978393 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: liraglutide
Description: High placebo treatment (3.0 mg) followed by low dose liraglutide treatment (1.8 mg). Injected s.c. (under the skin) once daily in the evening.
Study NCT00978393 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: liraglutide
Description: High dose liraglutide treatment (3.0) followed by low placebo treatment (1.8 mg). Injected s.c. (under the skin) once daily in the evening.
Study NCT00978393 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: liraglutide
Description: Low placebo treatment (1.8 mg) followed by high dose liraglutide treatment (3.0 mg). Injected s.c. (under the skin) once daily in the evening.
Study NCT03763058 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Music Therapy
Description: The music intervention is administered via a smartphone- (and computer-) based application called Music Care. The Music Care app is a receptive music intervention, allowing the patient to freely adjust the length of and choose the preferred style between different sequences of instrumental music. All musical pieces were recorded in high-quality recording studios with professional musicians. Music Care utilizes the U technique designed to gradually relax the listener. The U technique is implemented using a musical sequence of 20 minutes that was divided into 5 different musical pieces at 3 to 4 minutes each.~Participants will complete 1-2 sessions of listening to music per day, with a minimum of 15 sessions per month.
Study NCT01593254 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Imatinib
Study NCT01593254 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dasatinib
Study NCT02295267 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: walnut allergy provocation
Description: double blind placebo controlled food challenge
Study NCT01230216 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: control systolic blood pressure less than 120 mmHg
Description: use losartan to control blood pressure
Study NCT01230216 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: control systolic blood pressure less than 140 mmHg
Description: use losartan to control blood pressure
Study NCT01745107 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Prophylactic postoperative radiation therapy
Description: Prescription dose of 95%planning target volume(PTV) 50.4Gy/1.8Gy/28fractions for supraclavicular region and 95%PTV 56Gy/2Gy/28fractions for mediastinum which is delivered in 2 months after surgery.
Study NCT03544125 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Given IV
Study NCT03544125 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: Given PO
Study NCT01652625 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Yunnan Baiyao toothpaste
Description: The patients were instructed to brush the teeth twice daily for 5 days, using 1 gram of Yunnan Baiyao toothpaste (equivocal to approximately 6-7 lines on a standard toothbrush) for 3 minutes. 6.5 milligrams of Yunnan Baiyao active extract were contained in 1 gram of the toothpaste.
Study NCT01652625 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo toothpaste
Description: One gram of the placebo toothpaste was used twice daily by the control group patients. Except for the active Yunnan Baiyao extract, all ingredients contained in the placebo-toothpaste were the same as that in the experimental toothpaste.
Study NCT04273867 — intervention group
Intervention type: OTHER
Intervention: Chronic Hypersensitivity Pneumonitis Health Related Quality of Life Survey Instrument
Description: This survey has been developed and revised from prior qualitative research with CHP patients and will be used to better evaluate disease status and quality of life with CHP.
Study NCT00179894 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physician training
Description: Physicians are trained in guidelines for medication management.
Study NCT04629872 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fingolimod
Description: Patients randomized to fingolimod will also receive oral fingolimod (Gilenya, Novartis) at a dosage of 0.5 mg once daily, for three consecutive days, with the first dose being given at the time in which patients are enrolled which is more than 3 hour prior to mechanical thrombectomy.
Study NCT02131636 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AGN-199201
Description: AGN-199201 applied to the face once daily for 29 days.
Study NCT02131636 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle to AGN-199201
Description: Vehicle to AGN-199201 applied to the face once daily for 29 days.
Study NCT00609713 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Comprehensive behavioral weight control program
Description: Participants will meet weekly for 12 weeks, then every other week for 12 weeks, and once a month thereafter through week 52. Adolescents and parents will receive manuals that provide lessons and homework assignments for each meeting. The program for the first 22 weeks includes the following topics: 1) the causes of obesity; 2) components of healthy nutrition; 3) self-monitoring of calories, physical activity, and inactivity; 4) stimulus control procedures; 5) coping with high-risk social or psychological situations that trigger excess eating; 6) increasing physical activity; and 7) minimizing inactivity. At each session, participants will submit their self-monitoring diaries and completed homework. Incentives for completion of self-monitoring tasks are an integral part of the behavior modification program and a small gift certificate will be given to subjects for successful completion at each intervention session.
Study NCT00609713 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Individual 12-month nutrition education program
Description: The other half of the participants (44 subjects) will be randomized to this arm of the intervention (usual care), which will also start in five waves. In contrast to the comprehensive behavioral weight control program, the nutrition education program will take place through individual appointments with a clinical dietician to reflect usual care and mimic the present approach used for the treatment of obese adolescents at the Children's Hospital of Philadelphia (CHOP) Nutrition Consultation. Parents will be required to take part in the consultations. The first consultation will last 60 minutes and the following consultations of 30 minutes will take place once a month for the first six months, then every other month for the second six months, as is the usual practice in our clinical setting.
Study NCT01980498 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl pectin nasal spray (FPNS)
Description: The first dose of FPNS will be 100 mcg dose. It will be increased until 800 mcg dose.
Study NCT01980498 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Physician choice-Usual care (PC-UC)
Description: The PC-UC will be started at a dose according to the physician choice. If this dose of PC-UC is effective on pain control, at the following meal the patient will take the same dose of PC-UC.~If the dose of PC-UC results non effective on pain control, at the following meal the patient will take an increased dose of the same PC-UC drug or change the PC-UC drug, according to the physician choice.
Study NCT00776620 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glimepiride 1mg Tablets
Study NCT00776620 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glimepiride 1mg Tablets
Study NCT02350699 — intervention group
Intervention type: DEVICE
Intervention: Nautilus BrainPulse
Description: A noninvasive device to detect concussion utilizing headset and sensors
Study NCT02445859 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cefuroxime 4 hourly bolus
Description: Cefuroxime loading dose followed by a continuous infusion dosed according to renal function. Dosed to target a serum concentration of 64mg/L.
Study NCT02445859 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cefuroxime 4 hourly bolus
Description: Cefuroxime loading dose followed by a continuous infusion dosed according to renal function. Dosed to target a serum concentration of 64mg/L.
Study NCT04110496 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RTX-134
Description: RTX-134 is a cellular therapy containing AvPAL
Study NCT00346567 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zidovudine and Lamivudine (Combivir)
Study NCT00346567 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Emtricitabine and Tenofovir (Truvada)
Study NCT03749421 — intervention group
Intervention type: OTHER
Intervention: Prosigna PAM-50 assay
Description: Looks at the gene activity of a person's cancer cells to determine the likely outcome or course of a disease (prognosis) and predict the benefit of chemotherapy or endocrine therapy after breast surgery
Study NCT04282837 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: AI classification of patients with obesity
Description: Computational modeling techniques will be used for the precise reclassification of obesity into four subgroups, several variables according to the clinical experience and the modeling results will be selected for the cluster analysis.
Study NCT00650286 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Modafinil Tablets 200 mg
Description: 200mg, single dose fed
Study NCT00650286 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Provigil® Tablets 200 mg
Description: 200mg, single dose fed
Study NCT01449513 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ingenol mebutate
Description: 0.05% Ingenol mebutate Gel once daily for 2 consecutive days
Study NCT01449513 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Gel
Description: Gel vehicle of PEP005
Study NCT02039323 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir
Study NCT02039323 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Maraviroc
Study NCT03891823 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: MitraClip
Description: Study participants will be randomized to MitraClip device to determine treatment efficacy in improving LV remodelling or functional capacity.
Study NCT03891823 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MitraClip
Description: Study participants will be randomized to MitraClip device to determine treatment efficacy in improving LV remodelling or functional capacity.
Study NCT03891823 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Medical Therapy
Description: Study participants will be randomized to medical therapy to determine treatment efficacy in improving LV remodelling or functional capacity.
Study NCT03891823 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Medical Therapy
Description: Study participants will be randomized to medical therapy to determine treatment efficacy in improving LV remodelling or functional capacity.
Study NCT04102683 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Therapeutic recreation activity program
Description: The experimental recreation program, which consisted of two sessions per week and lasted approximately 1 hour each session, lasted for 8 weeks between March 2019 and May 2019 for the adolescents in the experimental group. The Therapeutic Recreation Activity Program, which consists of 16 sessions, is organized according to the self-determination and entertainment development model. This model aims to provide individual development and prosperity by creating an entertaining environment with therapeutic recreation. According to the degree of enjoyment, activity improves freedom of choice, preferences and ability to express oneself. Pleasure is a feeling that the participant feels deeply during therapeutic recreation. Provides entertainment experience. Pleasure increases individual motivation to participate, as well as making the best use of physical, social and emotional conditions.
Study NCT01180023 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sweeping
Description: Sweeping of membranes during digital exam
Study NCT01732445 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ruxolitinib phosphate
Description: Given PO
Study NCT01732445 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: danazol
Description: Given PO
Study NCT01732445 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: quality-of-life assessment
Description: Ancillary studies
Study NCT01732445 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: questionnaire administration
Description: Ancillary studies
Study NCT01004432 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Golimumab 50 mg SC
Description: Golimumab 50 milligram (mg) subcutaneous (SC) injection every 4 weeks.
Study NCT01004432 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Golimumab 2 mg/kg IV
Description: Golimumab 2 milligram per kilogram (mg/kg) intravenous infusion every 8 weeks.
Study NCT01004432 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX)
Description: Participants will continue taking their current Methotrexate (MTX) treatment regimen.
Study NCT01004432 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo SC
Description: Placebo matched to golimumab SC injection every 4 weeks.
Study NCT01004432 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo IV
Description: Placebo matched to golimumab intravenous infusion every 8 weeks.
Study NCT02394665 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Concurrently during radiation therapy. Adjuvant therapy administered daily on days 1 - 5 for 12 cycles. One cycle = 28 days:~* Concurrent during Radiation Therapy: 75 mg/m\^2 orally for 6 weeks;~* Post-radiation, adjuvant therapy: 150 mg/m\^2 - 200 mg/m\^2 orally daily on days 1 - 5 of each cycle.
Study NCT02394665 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Functional Assessment of Cancer Therapy-Brain (FACT-Br)
Description: FACT-Br Quality of Life (QOL) questionnaire to be completed by study patients as protocol specific timepoints
Study NCT02394665 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Radiosurgery Boost
Description: Patients will undergo SRS boost in a single fraction dose prior to IMRT treatment:~HTV Maximum dimension vs. Prescribed Dose to HTV: ≤ 20 mm = 21 Gy; 21 mm - 30 mm = 18 Gy; 31 mm - 40 mm = 15 Gy.
Study NCT02394665 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Simultaneous Integrated Boost
Description: Treatment shall consist of 60 Gy in 30 fractions to planning target volume (PTV) 60 and 75 Gy in 30 fractions to PTV 75.
Study NCT02394665 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 3D MRSI
Description: Three Dimensional Magnetic Resonance Spectroscopy Imaging (MRSI) during pre-treatment, week 3 during radiation therapy, end of radiation therapy; will include standard gadolinium enhanced MRI prior to cycle 1, 5, 9, and post cycle 12 of adjuvant temozolomide therapy, per protocol.
Study NCT01056263 — intervention group
Intervention type: DRUG
Intervention: axitinib: observational study
Description: Non-interventional observational study
Study NCT03981497 — intervention group
Intervention type: PROCEDURE
Intervention: Microwave ablation (MWA)
Description: Thermal ablation
Study NCT03860090 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Pacemaker implant
Description: Implantation of endovenous cardiac stimulation device.
Study NCT03860090 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Defibrillator implant
Description: Implantation of endovenous cardiac defibrillation device.
Study NCT03860090 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: AXILLARY VEIN ACCESS
Description: Fluoroscopy-guided axillary puncture to get vein access
Study NCT03860090 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: CEPHALIC VEIN ACCESS
Description: Optimized cephalic vein cutdown to get vein access
Study NCT02014883 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLUT1 DS
Study NCT03900429 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MGL-3196
Description: Tablet
Study NCT03900429 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching Tablets
Study NCT03900429 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Liver Biopsy
Description: A procedure in which a needle is inserted into the liver to collect a tissue sample
Study NCT03900429 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Liver Biopsy
Description: A procedure in which a needle is inserted into the liver to collect a tissue sample
Study NCT04403906 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: PCL COV05 - COVID 19 Ag Rapid FIA test (Rapid Antigen Test)
Description: The PCL COV05 - COVID 19 Ag Rapid FIA test has FSC and CE approvals for the qualitative detection of SARS-CoV-2 Antigens from human oropharyngeal swabs and deep sputum samples. The manufacturer is PCL Corporation Ltd 17F, 128 B-dong, Courthouse-ro, Songpa-gu, Seoul, South Korea.
Study NCT03371823 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Normotensive
Description: FMD is a measure of endothelial function by assessing the degree to which vessel dilates in response to increased flow. Pulse Wave Analysis and Pulse Wave Velocity assesses arterial stiffness and wave reflection in all women. Laser Doppler flowmetry is used in combination with cutaneous microdialysis as a minimally invasive technique to examine mechanisms of vascular function. ET-B and ET-A receptor antagonists will be perfused via intradermal microdialysis fibers while measuring cutaneous blood flow. ET-1 production and ET-B receptor expression in endothelial cells collected from an antecubital vein will also be assessed. Immunohistochemistry will be performed on skin punch biopsy samples to assess for protein expression of ET-A and ET-B receptors.
Study NCT03371823 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hypertensives
Description: ANG II increases the synthesis of ET-1 and alters ET-A/B receptor expression, thus affecting ET-1 bioavailability. Losartan is an ANG II receptor antagonist which attenuates ET-1 production. Losartan 50 mg daily is administered for 14 days to hypertensive women. FMD is used to measure endothelial function. Pulse Wave Analysis and Pulse Wave Velocity assesses arterial stiffness and wave reflection. Laser Doppler flowmetry with cutaneous microdialysis is used to examine vascular function when ET-A and ET-B receptor antagonists is perfused via intradermal microdialysis fibers. ET-1 production and ET-B receptor expression in endothelial cells collected from an antecubital vein will be assessed. Skin punch biopsy samples will be used to assess for protein expression of ET-A and ET-B receptors.
Study NCT02328586 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Group Acupuncture
Study NCT03259399 — intervention group
Intervention type: GENETIC
Intervention: detection of genotype
Description: detection of genotype by next generation sequencing
Study NCT00693433 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone
Description: Given orally
Study NCT00693433 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: temsirolimus
Description: Given IV
Study NCT00693433 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT04615598 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Action observation
Description: The idea is to show some videos with the aim of improving patients' tongue strength.
Study NCT04615598 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo group
Description: The idea is to show some videos of vegetation with the aim of having an intervention time but ineffective.
Study NCT00139581 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pimecrolimus
Description: Pimecrolimus cream 1 % applied twice daily (b.i.d.)
Study NCT00139581 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pimecrolimus
Description: Pimecrolimus cream 1 % applied once daily (o.d.) and placebo applied once daily (o.d.)
Study NCT02351713 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Continuous aerobic exercise prescribed according to two exercise intensity methods: threshold based method (i.e., ventilatory threshold) and relative percent method (i.e., heart rate reserve).